Speaker illustration

Professor Eric Velazquez

Yale University, New Haven (United States of America)

Member of:

European Society of Cardiology

Therapy with Sacubitril-Valsartan should begin in hospital - Rebuttal

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Treatment

Session: The Grand Debate 1: Advances in medical and interventional treatment of heart failure

Thumbnail

Therapy with Sacubitril-Valsartan should begin in hospital-Pro

Event: Heart Failure 2019 - 6th World Congress on Acute Heart Failure

Topic: Treatment

Session: The Grand Debate 1: Advances in medical and interventional treatment of heart failure

Thumbnail

Myocardial revascularisation - When, for whom and how

Event: Heart Failure 2018 & World Congress on Acute Heart Failure

Topic: Biomarkers

Session: Diagnosis and treatment of acute heart failure in acute coronary syndromes

Thumbnail

Coronary revascularisation provides no meaningful clinical benefit over optimal medical therapy in patients with stable ischaemic heart failure - CONTRA

Event: Heart Failure 2018 & World Congress on Acute Heart Failure

Topic: Treatment, Other

Session: GRAND DEBATE I - Drugs or interventions - The beat goes on

Thumbnail

Surgical revascularisation beats optimal medical therapy in ischaemic heart failure - PRO.

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Devices / Artificial heart / CRT / ICD

Session: STICH (Surgical Treatment for Ischemic Heart Failure)

Thumbnail

The effect of CABG by age in patients with heart failure: 10 year follow data from the STICHES study

Event: ESC CONGRESS 2016

Topic: Cardiac surgery

Session: Clinical Trial Update Coronary artery disease

Thumbnail

STICH at 10 years – Cardiologist approach.

Event: HEART FAILURE 2016

Topic: Surgery

Session: Revascularisation strategies in ischemic heart failure

Thumbnail

This platform is supported by

logo Novo Nordisk